1. SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1.
- Author
-
Dong F, He K, Zhang S, Song K, Jiang L, Hu LP, Li Q, Zhang XL, Zhang N, Li BT, Zhu LL, Li J, Feng M, Gao Y, Chen J, Hu X, Wang J, Jiang C, Wang C, Zhu HH, Da LT, Ji J, Zhang ZG, Bao Z, and Jiang SH
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Warburg Effect, Oncologic drug effects, Mice, Nude, Cell Proliferation drug effects, Antidepressive Agents pharmacology, Male, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular metabolism, Liver Neoplasms drug therapy, Liver Neoplasms pathology, Liver Neoplasms metabolism, Selective Serotonin Reuptake Inhibitors pharmacology, Citalopram pharmacology, Glucose Transporter Type 1 metabolism, Glucose Transporter Type 1 genetics
- Abstract
Selective serotonin reuptake inhibitors (SSRIs) have shown promise in cancer therapy, particularly for hepatocellular carcinoma (HCC), but their molecular targets and mechanisms remain unclear. Here, we show that SSRIs exhibit significant anti-HCC effects independent of their classical target, the serotonin reuptake transporter (SERT). Using global inverse gene expression profiling, drug affinity responsive target stability assays, and in silico molecular docking, we demonstrate that citalopram targets glucose transporter 1 (GLUT1), resulting in reduced glycolytic flux. A mutant GLUT1 variant at the citalopram binding site (E380) diminishes the drug's inhibitory effects on the Warburg effect and tumor growth. In preclinical models, citalopram dampens the growth of GLUT1
high liver tumors and displays a synergistic effect with anti-PD-1 therapy. Retrospective analysis reveals that SSRI use correlates with a lower risk of metastasis among patients with HCC. Our study describes a role for SSRIs in cancer metabolism, establishing a rationale for their repurposing as potential anti-cancer drugs for HCC., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF